British pharmaceutical group AstraZeneca has held talks with US rival Bristol Myers Squibb about a merger valued at nearly $400 billion, The Financial Times has reported. AstraZeneca, which declined to comment Monday in a message to AFP, saw its share price slump more than seven percent in early London trading following the report, published Sunday. […]
The post Drug giants AstraZeneca, BMS weighing $400 bn tie-up: report appeared first on Insider Paper.
